We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-1.36%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.12B
AUM Growth
-$192M
(-15%)
Cap. Flow
-$62M
Cap. Flow
% of AUM
-5.56%
Top 10 Holdings %
Top 10 Hldgs %
59.87%
Holding
40
New
7
Increased
9
Reduced
19
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PVLA
Palvella Therapeutics
PVLA
|
+$28.3M |
| 2 |
TriSalus Life Sciences
TLSI
|
+$24.8M |
| 3 |
GeneDx Holdings
WGS
|
+$22.2M |
| 4 |
Apogee Therapeutics
APGE
|
+$21.2M |
| 5 |
Omnicell
OMCL
|
+$20.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$41.5M |
| 2 |
Axogen
AXGN
|
+$40M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$38.9M |
| 4 |
Vera Therapeutics
VERA
|
+$23.9M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
GeneDx Holdings
WGS
$1.75B
| $15.6M | 1.4% |
+242,927
| New | +$22.2M |
|
27
Wave Life Sciences
WVE
$1.12B
| $13.4M | 1.2% |
1,843,968
-9,883
| -0.5% | -$129K |
|
|
28
Vera Therapeutics
VERA
$2.54B
| $12.6M | 1.13% |
313,906
-555,770
| -64% | -$23.9M |
|
29
MiMedx Group
MDXG
$626M
| $11.2M | 1.01% |
2,842,892
-196,449
| -6% | -$990K |
|
30
Butterfly Network
BFLY
$1.72B
| $10.7M | 0.96% |
2,660,167
-151,964
| -5% | -$587K |
|
|
SGP
31
SpyGlass Pharma
SGP
$685M
| $9.72M | 0.87% |
+375,000
| New | +$10.1M |
|
32
Organogenesis Holdings
ORGO
$308M
| $8.29M | 0.74% |
3,498,533
-364,287
| -9% | -$1.26M |
|
33
Vaxcyte
PCVX
$7.89B
| $8.24M | 0.74% |
+141,784
| New | +$7.7M |
|
34
Enliven Therapeutics
ELVN
$3.78B
| $7.91M | 0.71% |
+201,867
| New | +$5.59M |
|
|
35
Rhythm Pharmaceuticals
RYTM
$7B
| $7.58M | 0.68% |
87,181
-208,663
| -71% | -$20.3M |
|
|
ABVX
36
Abivax
ABVX
$11B
| – | – |
-88,674
| Closed | -$12M |
|
37
Dyne Therapeutics
DYN
$4.04B
| – | – |
-155,231
| Closed | -$3.04M |
|
|
38
Disc Medicine
IRON
$2.83B
| – | – |
-523,167
| Closed | -$41.5M |
|
39
iShares Russell 2000 Growth ETF
IWO
$14.5B
| – | – |
-760
| Closed | -$245K |
|
|
40
Madrigal Pharmaceuticals
MDGL
$12.6B
| – | – |
-66,831
| Closed | -$38.9M |
|
Similar funds
AIM
MTCM
CNC
ACG
C
NOSC
RIM
CT
First Light Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, First Light Asset Management held 40 positions worth $1.12B, down 15% from $1.31B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
First Light Asset Management withdrew a net $62M in Q1 2026, closing 5 positions and reducing 19 holdings. Its most notable exit was Disc Medicine, an estimated $41.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
Against the trend, First Light Asset Management opened a new position in TriSalus Life Sciences worth $20.3M.
- First Light Asset Management's largest Q1 2026 buy was TriSalus Life Sciences: 5,066,827 shares worth $20.3M.
- First Light Asset Management added most to Palvella Therapeutics in Q1 2026, an estimated $28.3M increase.
- First Light Asset Management's biggest Q1 2026 reduction was Axogen, cutting an estimated $40M.
- First Light Asset Management fully exited Disc Medicine in Q1 2026, selling an estimated $41.5M.
- First Light Asset Management's ten largest holdings make up 60% of its $1.12B portfolio in Q1 2026.
- First Light Asset Management opened 7 new positions and closed 5 in Q1 2026.
- First Light Asset Management's portfolio value fell 15% quarter-over-quarter to $1.12B.
Based on First Light Asset Management's 13F filing for Q1 2026, filed 15 May 2026.